The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000736347
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
8/05/2026
Date registered
Help: Date registered
18/06/2026
Date last updated
Help: Date last updated
28/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
18/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
EVADE-1: A Phase 2a pilot study of evexomostat in patients with metastatic castration-resistant prostate cancer.
Scientific title
EVADE-1: A Phase 2a pilot study of evexomostat in patients with metastatic castration-resistant aggressive variant prostate cancer as defined by prostate specific membrane antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT)
Additional trial identifiers [1] 317227 0
SDX-0104
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Castration-resistant aggressive variant prostate cancer 341833 0
Condition category
Condition code
Cancer 337904 337904 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Evexomostat (SDX-7320)
Dose: 49mg/m^2, every 14 days, up to 12 doses
Study duration: 24 weeks
Mode of delivery: Subcutaneous injection
Monitoring, administration in hospital setting
Intervention code [1] 334000 0
Treatment: Drugs
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345350 0
Radiographic disease progression by longitudinal monitoring of 68Ga-PSMA-PET/CT.
Timepoint [1] 345350 0
Baseline, Week 4 to Week 5 post-treatment commencement (following dose 3), Week 12 to Week 13 post-treatment commencement (following dose 7), and Week 22 to Week 23 post-treatment commencement (following dose 12).
Secondary outcome [1] 461354 0
Change in PSMA-high tumour lesion heterogeneity assessed using longitudinal 68Ga-PSMA PET/CT.
Timepoint [1] 461354 0
Baseline, Week 4 to Week 5 post-treatment commencement, Week 12 to Week 13 post-treatment commencement, and Week 22 to Week 23 post-treatment commencement.
Secondary outcome [2] 461355 0
Change from baseline in circulating tumour DNA (ctDNA) levels.
Timepoint [2] 461355 0
Baseline, Week 4, Week 10, Week 16, and End of Study Week 26 post-treatment commencement.
Secondary outcome [3] 461356 0
Change from baseline in serum prostate-specific antigen (PSA) levels.
Timepoint [3] 461356 0
Baseline, protocol-specified treatment visits, and End of Study Week 26 post-treatment commencement.
Secondary outcome [4] 462866 0
Change in FDG-avid disease burden assessed by longitudinal 18F-FDG PET/CT.
Timepoint [4] 462866 0
Baseline, Week 4 to Week 5 post-treatment commencement, Week 12 to Week 13 post-treatment commencement, and Week 22 to Week 23 post-treatment commencement.
Secondary outcome [5] 462867 0
Change from baseline in circulating metabolic and adipokine biomarkers.
Timepoint [5] 462867 0
Baseline, Week 4, Week 10, Week 16, and End of Study Week 26 post-treatment commencement.
Secondary outcome [6] 462868 0
Change from baseline in circulating inflammatory biomarkers.
Timepoint [6] 462868 0
Baseline, Week 4, Week 10, Week 16, and End of Study Week 26 post-treatment commencement.
Secondary outcome [7] 462869 0
Change from baseline in circulating angiogenic biomarkers.
Timepoint [7] 462869 0
Baseline, Week 4, Week 10, Week 16, and End of Study Week 26 post-treatment commencement.

Eligibility
Key inclusion criteria
1. Participant signed Informed Consent
2. Participant is 18 years old or older.
3. Participants enrolled must have mCRPC with at least 1 metastatic site that measures at least 10mm in diameter.
4. Participants have at least one (1) measurable progressing lesion which is PSMA low and/or FDG-avid. Low PSMA avidity on 68Ga-PSMA PET/CT is defined as SUVmax of less than 15 on at least one measurable lesion. FDG avid refers to at least one (1) PSMA-negative /FDG-positive discordant lesion.
5. Participants with de novo diagnosis of AV metastatic prostate cancer are allowed.
6. Participants who may have received previous androgen receptor pathway inhibitor(s) including apalutamide, enzalutamide, darolutamide, or abiraterone,
7. Participants must be on ADT.
8. Participant may have received a taxane-based chemotherapy and/or radiation for their advanced disease, with treatment having been at least four (4) weeks prior to first dose of evexomostat in this study
9. Participants are allowed prior PARP inhibitor treatment for BRCA1/2 mutation prostate cancer.
10. Participants are allowed to have had prior experimental antibody-drug conjugate treatment for their metastatic disease, but not for the AV disease treatment.
11. All participants should be receiving a bone-protecting agent (BPA) prior to study start
12. ECOG performance status of 2 or greater.
13. Adequate renal function: defined as Creatinine clearance of at least 50mL/ min (using either the Cockcroft-Gault equation or the CKD-EPI formula for calculation of eGFR or has chronic kidney disease (CKD) grade equal to 1.) Alternatively, a 24-hour urine test can be performed to confirm renal sufficiency.
14. Adequate liver function:
a. Bilirubin less than 1.5 of the upper limit of normal (ULN) (or if bilirubin is between 1.5 and 2 times the ULN, must have a normal conjugated bilirubin)
b. AST or ALT equal to 2.5 times the ULN (or equal to 5.0 times the ULN in the presence of liver metastases)
15. Adequate bone marrow function:
a. Platelets equal to 120 (times 10 to the 9) per litre
b. Haemoglobin of 90g per litre (no red blood cell transfusion in last 4 weeks)
c. Neutrophils at least 1.5 (times 10 to the 9) per litre
d. White blood cells of 2,500 cells per microlitre or greater
e. Albumin of 30 gm per litre or above
16. Estimated life expectancy of at least 6 months
17. Participants must have the ability to understand and sign an approved informed consent form (ICF) and comply with all protocol requirements including agreement for intervals of PET-CT scans.


Minimum age
18 Years
Maximum age
No limit
Sex
Males
Healthy volunteers
No
Key exclusion criteria
1. Prior treatment with any PSMA-targeted radioligands/ radionuclides.
2. Participant received myelosuppressive therapy including docetaxel or cabazitaxel, within the last 4 weeks prior to planned first dose of evexomostat.
3. Participant received platinum-based or a topoisomerase inhibitor for their advanced or metastatic AVPC disease.
4. Participant is diagnosed with BRCA1/2 mutation and has not received prior treatment with a PARP inhibitor.
5. Participant has ongoing toxicities related to prior anti-cancer therapies that have not resolved to: platelets at least 120 (times 10 to the 9) per litre, ANC of 1500 per mL or greater, haemoglobin of 90g per litre or greater, and Grade 1 for other toxicities, per National Cancer Institute Common Terminology Criteria for Adverse Events.
6. Participant has an established diagnosis of type 1 diabetes mellitus or insulin dependent type 2 diabetes.
7. Participant is currently receiving any of the following medications and cannot be discontinued at least 7 days prior to the start of the treatment:
a. Strong cytochrome P450 3A4 (CYP3A4) inducers or inhibitors
b. Sulfonylurea-based anti-diabetic drugs (e.g., glipizide, glyburide)
8. Concurrent illness, including severe infection that may jeopardise the ability of the participant to undergo the procedures outlined in this protocol with reasonable safety
9. Participant has any other concurrent, severe and/or uncontrolled medical condition that would, in the Investigator’s judgement, contra-indicate patient participation in the clinical study (e.g., chronic active hepatitis, severe hepatic impairment, recent cardiac events, uncontrolled heart disease, additional cancerous lesions not related to their prostate cancer)
10. Patient participated in a prior investigational study within 21 days prior to the start of study treatment or within 4 half-lives of the investigational product, whichever is shorter.
11. Unsuitable for repeated PET-CT imaging.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1 / Phase 2
Type of endpoint/s
Efficacy
Statistical methods / analysis
No formal sample size calculation has been performed. This is a Phase IIa, single-arm, open-label pilot study designed to recruit up to 15 participants with metastatic castration-resistant prostate cancer who meet the eligibility criteria. The sample size is considered appropriate for an exploratory pilot study intended to assess feasibility, safety, tolerability and preliminary signals of anti-cancer activity in this imaging-defined population. The statistical power will be driven by the quantitative PET/CT image analysis using within-patient analyses of individual metastases and quantitative total-body imaging.

All analyses will be descriptive and hypothesis-generating. The Safety population will include all enrolled participants who receive at least one dose of evexomostat. The Efficacy population will include all enrolled participants who receive at least one dose of evexomostat and have at least one post-dose efficacy or tumour assessment. Quantitative variables will be summarised using number, mean, standard deviation, median, minimum and maximum. Categorical variables will be summarised using number and percentage. Demographic and baseline disease characteristics will be summarised descriptively.

The primary imaging outcome, radiographic disease progression assessed by longitudinal 68Ga-PSMA PET/CT, will be summarised descriptively using quantitative imaging measures including SUVmax, tumour SUVmean and total PSMA-positive tumour volume. Imaging will be centrally analysed using nuclear medicine metastasis tracking software (MIM). Radiographic progression will be assessed using RECIP v1.0, with PCWG4 considered where applicable and PSA criteria excluded.

Secondary imaging analyses will descriptively summarise changes in 18F-FDG PET/CT-derived disease burden and PSMA-high tumour lesion heterogeneity. Quantitative total-body imaging and radiomic measures may be used to assess lesion-level heterogeneity. Exploratory analyses may assess relationships between PSMA PET/CT findings, FDG PET/CT findings, visual assessment scores, quantitative total-body imaging measures, RECIP v1.0 assessment, PSA, circulating tumour DNA and clinical outcomes. Visual assessment scores will be derived for PET imaging timepoints by nuclear medicine personnel at the Herston Imaging Research Facility (HIRF) using a pre-developed model.

Exploratory biomarker analyses will descriptively summarise changes from baseline in circulating tumour DNA, PSA, pharmacokinetic measures, metabolic and adipokine biomarkers, inflammatory biomarkers and angiogenic biomarkers. Exploratory analyses may assess relationships between biomarker changes, imaging outcomes, safety outcomes and clinical outcomes. Given the pilot sample size, these analyses will not be used for formal hypothesis testing. Future genomic or mutation-profile analyses may be undertaken only where consistent with participant consent and relevant ethics approvals.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 29490 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 45807 0
4102 - Woolloongabba

Funding & Sponsors
Funding source category [1] 321804 0
Government body
Name [1] 321804 0
US Department of Defense (PCRP Translational Science Award)
Country [1] 321804 0
United States of America
Primary sponsor type
University
Name
Queensland University of Technology
Address
Country
Australia
Secondary sponsor category [1] 324659 0
None
Name [1] 324659 0
Address [1] 324659 0
Country [1] 324659 0
Other collaborator category [1] 283930 0
Government body
Name [1] 283930 0
Metro South Health, Brisbane
Address [1] 283930 0
Country [1] 283930 0
Australia
Other collaborator category [2] 283931 0
Commercial sector/Industry
Name [2] 283931 0
SynDevRx, Inc
Address [2] 283931 0
Country [2] 283931 0
United States of America
Other collaborator category [3] 283949 0
University
Name [3] 283949 0
Herston Imaging Research Facility
Address [3] 283949 0
Country [3] 283949 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320349 0
Metro South Human Research Ethics Committee
Ethics committee address [1] 320349 0
Ethics committee country [1] 320349 0
Australia
Date submitted for ethics approval [1] 320349 0
14/05/2026
Approval date [1] 320349 0
24/07/2026
Ethics approval number [1] 320349 0
HREC/QMS/124843

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150178 0
Prof Aaron Hansen
Address 150178 0
Princess Alexandra Hospital, Ipswich Rd, Brisbane, Qld, 4102
Country 150178 0
Australia
Phone 150178 0
+61 7 3176 5564
Fax 150178 0
Email 150178 0
Contact person for public queries
Name 150179 0
Prof Colleen Nelson
Address 150179 0
Queensland University of Technology, 2 George St, Brisbane, Qld, 4000
Country 150179 0
Australia
Phone 150179 0
+61 7 3176 7443
Fax 150179 0
Email 150179 0
Contact person for scientific queries
Name 150180 0
Prof Colleen Nelson
Address 150180 0
Queensland University of Technology, 2 George St, Brisbane Queensland 4000
Country 150180 0
Australia
Phone 150180 0
+61 7 3176 7443
Fax 150180 0
Email 150180 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Ethical approval    Link will be provided following HREC approval
Study protocol    Link will be provided following HREC approval


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.